203 related articles for article (PubMed ID: 34325934)
21. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
Fitzpatrick MC; Laufer RS; Baral R; Driscoll AJ; Feikin DR; Fleming JA; Jit M; Kim S; Koltai M; Li Y; Li X; Nair H; Neuzil KM; Pecenka C; Sparrow E; Srikantiah P; Ortiz JR
Vaccine; 2023 Nov; 41(48):7047-7059. PubMed ID: 37777450
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
[TBL] [Abstract][Full Text] [Related]
23. Epidemiology, Risk Factors, and Outcomes of Respiratory Syncytial Virus Infections in Newborns in Bamako, Mali.
Buchwald AG; Tamboura B; Tennant SM; Haidara FC; Coulibaly F; Doumbia M; Diallo F; Keita AM; Sow SO; Kotloff KL; Levine MM; Tapia MD
Clin Infect Dis; 2020 Jan; 70(1):59-66. PubMed ID: 30810160
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
25. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
26. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
[TBL] [Abstract][Full Text] [Related]
27. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
Wittenauer R; Pecenka C; Baral R
BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
[TBL] [Abstract][Full Text] [Related]
28. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
Mazur NI; Terstappen J; Baral R; Bardají A; Beutels P; Buchholz UJ; Cohen C; Crowe JE; Cutland CL; Eckert L; Feikin D; Fitzpatrick T; Fong Y; Graham BS; Heikkinen T; Higgins D; Hirve S; Klugman KP; Kragten-Tabatabaie L; Lemey P; Libster R; Löwensteyn Y; Mejias A; Munoz FM; Munywoki PK; Mwananyanda L; Nair H; Nunes MC; Ramilo O; Richmond P; Ruckwardt TJ; Sande C; Srikantiah P; Thacker N; Waldstein KA; Weinberger D; Wildenbeest J; Wiseman D; Zar HJ; Zambon M; Bont L
Lancet Infect Dis; 2023 Jan; 23(1):e2-e21. PubMed ID: 35952703
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis.
Hodgson D; Pebody R; Panovska-Griffiths J; Baguelin M; Atkins KE
BMC Med; 2020 Nov; 18(1):348. PubMed ID: 33203423
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
31. Mathematical modelling of respiratory syncytial virus (RSV) in low- and middle-income countries: A systematic review.
Mezei A; Cohen J; Renwick MJ; Atwell J; Portnoy A
Epidemics; 2021 Jun; 35():100444. PubMed ID: 33662812
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making.
Strutton DR; Stang PE
J Pediatr; 2003 Nov; 143(5 Suppl):S157-62. PubMed ID: 14615715
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
[TBL] [Abstract][Full Text] [Related]
34. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
[TBL] [Abstract][Full Text] [Related]
35. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
36. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
38. The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.
Bos JM; Rietveld E; Moll HA; Steyerberg EW; Luytjes W; Wilschut JC; de Groot R; Postma MJ
Vaccine; 2007 Sep; 25(39-40):6922-9. PubMed ID: 17707959
[TBL] [Abstract][Full Text] [Related]
39. The preventive effect of vaccine prophylaxis on severe respiratory syncytial virus infection: A meta-analysis.
Zhu T; Zhang C; Yu L; Chen J; Qiu H; Lyu W; Huang S
Virol Sin; 2015 Oct; 30(5):371-8. PubMed ID: 26511990
[TBL] [Abstract][Full Text] [Related]
40. Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.
Chu HY; Tielsch J; Katz J; Magaret AS; Khatry S; LeClerq SC; Shrestha L; Kuypers J; Steinhoff MC; Englund JA
J Clin Virol; 2017 Oct; 95():90-95. PubMed ID: 28903080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
